Company Interview / Neuren's FDA fast track

Key points:

Fast track designation from the FDA for Neuren’s NNZ-2591 across three programsLaunch of phase 3 "Koala" trial, last step to filing for approvalStrong financial position supported by DAYBUE sales in the USIncreased focus on growth and further clinical milestones for NNZ-2591

Neuren Pharmaceuticals chief executive Jon Pilcher expresses optimism as the company secures fast track designation from the US Food and Drug Administration for its treatment targeting a rare genetic disorder, Phelan-McDermid Syndrome. Pilcher states that the FDA’s decision reflects the serious nature of the condition and the current lack of approved therapies, adding that enhanced engagement with the US regulator could lead to a more expedited review process. He emphasises how this designation now extends across three programs for Neuren’s lead treatment, NNZ-2591, highlighting the company’s strengthened position in the clinical landscape.

Pilcher says the launch of the phase 3 "Koala" clinical trial for NNZ-2591 marks a significant milestone, coinciding with Phelan-McDermid Syndrome Awareness Day. With an agreement in place for rapid filing should results prove positive, he notes the "Koala" trial brings an "Aussie flavour" to an international clinical effort, aiming to resonate with patient communities and their families. Pilcher also points to Neuren’s active engagement at the Canaccord Drug and Device Investor Conference in Noosa, uniting leading biotech firms and fund managers for in-depth sector interaction.

Turning to commercial progress, Pilcher provides an update on DAYBUE, Neuren’s first approved drug in the United States. He points to strong quarterly performance and growth potential, with only a third of eligible patients currently accessing treatment, leaving room for expansion. Pilcher describes Neuren’s financials as robust, driven by DAYBUE revenue, providing the foundation for continued investment and potential upside if NNZ-2591 succeeds in multiple indications.